Hepatology

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

With HepQuant DuO and SHUNT tests, investigators could categorize patients with sclerosing cholangitis into low, moderate, and high disease severity subgroups.

Reau explains the importance of second- and third-line treatment in PBC and the potential implications of no longer having OCA after a negative FDA advisory committee meeting.

Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

Moser reviews ongoing unmet needs in PBC and how the addition of 2 new second-line treatment options has changed the treatment landscape.

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Low birth weight and being small for gestational age were linked to a greater risk of developing pediatric-onset MASLD and progressive liver disease.

Findings underscore the importance of alcohol cessation in patients with steatotic liver disease, suggesting a synergistic effect between steatosis and alcohol on disease progression.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

People with chronic liver disease were more likely to experience healthcare barriers and require recurrent acute care compared to those with COPD and/or CVD.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

The decision to revoke the conditional marketing authorization is based on a June 2024 CHMP recommendation from the EMA suggesting the benefits of Ocaliva do not outweigh its risks.

A study suggests transient elastography and fibrosis-4 index may be effective in predicting hepatocellular carcinoma risk in hepatitis C patients.

Data for more than 2 million blood donors in Canada provides insight into HCV antibody positivity trends in this notoriously low-risk patient population.

The restrictive strategy led to fewer cholecystectomies without increasing complications but did not improve pain-free outcomes versus usual care for symptomatic cholelithiasis.

Endoscopic ultrasound-guided rendezvous technique and precut sphincterotomy had similar technical success, and failure with one method could be successfully cannulated with the other.

A study found that women with trauma history have reduced liver transplant access compared to men, with gender disparities not driven by psychiatric symptoms.

A new study found hepatitis C virus reinfections may occur within 24 weeks of sustained virologic response after injecting drugs.